Press Release: Mirexus Asset Deal
Mibelle Biochemistry expands portfolio with Mirexus Inc. asset deal
Mibelle Biochemistry announces the successful completion of an asset deal with Mirexus Inc., a Canadian company that offers a sustainable plant-derived glycogen (phytoglycogen) called PhytoSpherix™ for use in personal care products. The transition became effective October 1st, 2022 and under the terms of the agreement, both parties accepted to not disclose further details. The branded products PhytoSpherix™, EnerZea™, Adveen™ and Susttain™ are fully integrated in the portfolio of Mibelle Biochemistry and are available for purchase immediately at Mibelle Biochemistry.
“I am very excited about this asset deal, as we had been looking around for quite a while to find a perfect target, matching our philosophy ‘inspired by nature – realized by science’ and similarly fitting smoothly into our existing product portfolio,“ said Cornelia Schürch, Managing Director at Mibelle Biochemistry. “PhytoSpherix™ is finally fulfilling both requirements.”
“All of us at Mirexus are thrilled to find the ideal home for our technology at Mibelle Biochemistry. The deep knowledge and capabilities of Mibelle will enable the growth of this technology beyond what Mirexus could do on its own. We look forward to seeing the continued expansion of our technology under Mibelle’s experienced leadership”, said Phil Whiting, President & CEO of Mirexus Biotechnologies Inc.
The completion of this asset deal strengthens Mibelle Biochemistry’s active ingredient portfolio and enhances its position as a developer and manufacturer of unique, high-quality active ingredients for the cosmetic and nutraceutical industry. The new assets also drive Mibelle Biochemistry’s sustainable innovation efforts by further aligning the portfolio with the rising demand for natural and sustainable ingredients, Schürch further explains.
Find more about PhytoSpherix™ here.